The MHRA invites health institutions in Great Britain to share their experience of the health institution exemption (sometimes referred to as an in-house manufacturing exemption).
Similar Posts
Transparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2024-25
MHRA transactions over £500 made using the government procurement card (GPC).
UK sets out world‑leading pathway for space‑manufactured drugs
Patients could benefit from more effective, higher quality and longer lasting medicines as the UK sets out a clearer route to bring drugs manufactured in space safely to market.
Guidance: Medical devices: Standardised format for the periodic safety update report
Information and recommendations for manufacturers on the preparation and presentation of a periodic safety update report (PSUR).
Trinity Biotech Premier Hb9210™ HbA1c Analyser: Risk of Positive Bias and Updates to Instructions for Use (IFU), including use as a diagnostic aid in diabetes mellitus (DSI/2025/003)
The MHRA has received reports describing a positive bias in HbA1c results delivered by the Trinity Biotech Premier Hb9210 HbA1c analyser, which has resulted in patients being incorrectly diagnosed as pre-diabetic or diabetic.
UK clinical trial approval times twice as fast with AI and reforms
Patients receive earlier access to life-saving treatments as UK trial approval times cut in half from 91 to just 41 days.
Decision: Marketing authorisations Granted in 2026
Marketing authorisations Granted in 2026.